Market Place
Sourcing Support
VistaGen fails phase 2 depression trial, sparking stock rout
15 Nov 2019 //
FIERCE BIOTECH
Microcap biotech VistaGen turned to pennystock after PhII result depression drug
03 May 2019 //
ENDPTS
VistaGen - Nanocap CNS Drug Chasing Ketamine Fame
21 May 2018 //
SEEKING ALPHA
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
05 Apr 2018 //
PRESS RELEASE
Investors unimpressed with VistaGen update on AV-101; shares down 16%
30 Dec 2017 //
SEEKING ALPHA
How Ketamine could cure depression
30 Jan 2017 //
DRUG TARGET REVIEW
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.